Riskpilot← Back to searchSign inGet full accessRenovaro Biosciences Denmark ApS
APSActiveCVR 26027322Stumpedyssevej 17Research and experimental development on natural sciences and engineering · NACE 7210Est. 20011 employees
Revenue 2025
DKK -5K
-94% vs 2024
EBITDA margin
100.0%
+94% vs 2024
Equity ratio
-686089.7%
Financial strength
Net profit 2025
DKK -4,6M
+26% vs 2024
| Revenue | DKK -5K | -94% |
| EBITDA | DKK -5K | +94% |
| Net profit | DKK -4,6M | +26% |
| Total assets | DKK 13K | -99% |
| Equity | DKK -90,8M | -5% |
| Employees | 1 | — |
Legal name
Renovaro Biosciences Denmark ApS
CVR number
26027322
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. april 2001
Share capital
DKK 4.003.089
Employees
1 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at drive forskning, handel, fabrikation og dermed beslægtet virksomhed primært inden for medicinalbranchen.
Address
Stumpedyssevej 17
Phone
+4531334811
Email
an@rsgroup.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -365 | -211 | -1.201 | -80 | -5 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -365 | -211 | -2.189 | -80 | -5 |
| Depreciation & amort. | -99 | -99 | -81 | -68 | -166 |
| EBIT | -464 | -310 | -2.270 | -148 | -170 |
| Net financials | -2.669 | -9.954 | 107 | -6.070 | -4.460 |
| Profit before tax | -3.134 | -10.264 | -2.163 | -6.218 | -4.630 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -3.134 | -10.264 | -2.163 | -6.218 | -4.630 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2.101 | 1.267 | 1.467 | 1.397 | 13 |
| Equity | -67.481 | -77.745 | -79.908 | -86.126 | -90.756 |
| Long-term debt | 68.738 | 78.648 | 81.231 | 87.287 | 0 |
| Short-term debt | 843 | 363 | 144 | 236 | 90.769 |
| Total debt | 69.582 | 79.011 | 81.375 | 87.523 | 90.769 |
EBITDA margin
-459600.0%
This company
15.8%
Market median
-2908961% vs market
20212025
Equity ratio
-686089.7%
This company
38.2%
Market median
-1796146% vs market
20212025
Return on equity
-462995900.0%
This company
18.4%
Market median
-2516282165% vs market
20212025
Net profit margin
-462995900.0%
This company
8.1%
Market median
-5715998865% vs market
20212025
Asset turnover
-0.35×
This company
1.12×
Market median
-131% vs market
20212025
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DH Management | Management | 2024 |
| Former (7) | ||
EJ Chief Executive Officer | Chief Executive Officer | 2011 – 2018 |
KH | Audit | 2003 – 2004 |
HG Chief Executive Officer | Chief Executive Officer | 2018 – 2022 |
MZ Chief Executive Officer | Chief Executive Officer | 2007 – 2010 |
PA Management | Management | 2001 – 2001 |
FB Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
SF Chief Executive Officer | Chief Executive Officer | 2003 – 2004 |
| Name | Role | Member since |
|---|---|---|
| Former (23) | ||
| Board of Directors | 2005 – 2009 | |
| Board of Directors | 2007 – 2010 | |
| Board of Directors | 2001 – 2001 | |
| Board of Directors | 2003 – 2003 | |
| Board of Directors | 2011 – 2012 | |
| Chairman | 2012 – 2013 | |
| Board of Directors | 2001 – 2003 | |
| Chairman | 2010 – 2012 | |
| Chairman | 2003 – 2004 | |
| Board of Directors | 2012 – 2013 | |
| Board of Directors | 2001 – 2002 | |
| Board of Directors | 2003 – 2010 | |
| Board of Directors | 2013 – 2016 | |
| Chairman | 2013 – 2017 | |
| Chairman | 2017 – 2018 | |
| Board of Directors | 2013 – 2017 | |
| Chairman | 2009 – 2010 | |
| Chairman | 2001 – 2001 | |
| Board of Directors | 2012 – 2013 | |
| Board of Directors | 2004 – 2005 | |
| Board of Directors | 2010 – 2011 | |
| Board of Directors | 2012 – 2013 | |
| Chairman | 2003 – 2003 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Renovaro Biosciences Denmark ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| David Hershel Weinstein | Management | 0 companies |
| Eric Jean Marie Leire | Chief Executive Officer | 0 companies |
| Kristian Henning Pryds | Audit | 0 companies |
| Henrik Grønfeldt-Sørensen | Chief Executive Officer | 0 companies |
| Mai-Britt Zocca | Chief Executive Officer | 0 companies |
| Peter Andreas Stakemann | Management | 0 companies |
| Francois Binette | Chief Executive Officer | 0 companies |
| Suzanne Flagstad | Chief Executive Officer | 0 companies |
| Kaare Fiala | Board of Directors | 0 companies |
| Ulrik Finnemann | Board of Directors | 0 companies |
| Annemette Heller | Board of Directors | 0 companies |
| John René Frederiksen | Board of Directors | 0 companies |
| Peter Brincker Møller | Board of Directors | 0 companies |
| Knud Carsten Bernhard Lønfeldt | Chairman | 0 companies |
| Steen Lindkær-Jensen | Board of Directors | 0 companies |
| Dina Asmussen | Chairman | 0 companies |
| Mogens Trygve Lied Flagstad | Chairman | 0 companies |
| Sune Olsen | Board of Directors | 0 companies |
| Steen Sindet-Pedersen | Board of Directors | 0 companies |
| Mogens Helweg Claesson | Board of Directors | 0 companies |
| Jacob Rosenberg | Board of Directors | 0 companies |
| Niels Erik Nielsen | Chairman | 0 companies |
| Torben Bjørn Christensen | Chairman | 0 companies |
| Aldo Michael Noes Petersen | Board of Directors | 0 companies |
| Jesper Zeuthen | Chairman | 0 companies |
| Kim Madsen | Chairman | 0 companies |
| Peter Buhl | Board of Directors | 0 companies |
| Angela Rossetti | Board of Directors | 0 companies |
| Paul Laursen | Board of Directors | 0 companies |
| M.R. Tongtis Tongyai | Board of Directors | 0 companies |
| Henrik Irgang Elsner | Chairman | 0 companies |